GCIG/JGOG3017
Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary
SGCTG
GOG0281
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Trial Number
NCT02101788 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
GOG0277
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observtion in Treating Patients with High Risk Uterine Leiomyosarcoma Previously removed by Surgery
Trial Number
NCT01533207 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
FIRST-ENGOT-Ov44 (ENGOT/GCIG/Tesaro)
A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Trial Number
NCT03602859 (ClinicalTrials.gov ID)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
OReO-ENGOT-Ov38 (ENGOT/GCIG/AZ)
Phase III study Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer
Trial Number
NCT03106987 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
EORTC 62113-55115
A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
Trial Number
NCT01979393 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ENGOT-cx8/ GOG-3024/GCT1015-05
A Phase 1b/2 open-Label Trial of Tisotumab Vedotin (Humax-TF-ADC) Monotherapy and in combination with other Agents in Subjects with recurrent or Stage IVB Cervical Cancer